- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:46 | Former CinCor execs reunite to helm new biotech startup | ||
| Mo | ATyr shares plunge on trial miss in inflammatory lung disease | ||
| Mo | A key CDC panel meets this week to discuss vaccines. Here's what to know. | ||
| Mo | Novartis dives deeper into protein degraders with second Monte Rosa deal | ||
| Mo | Working smarter: best practices for thermal modeling in cold chain packaging design | ||
| Mo | Reaching more patients: How AI and data drive better representation in clinical trials | ||
| Fr | Takeda poaches top Lilly exec; Maze soars on early PKU drug data | ||
| Fr | Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology | ||
| Do | Prasad regains role as FDA's top doctor, scientist | ||
| Do | Child dies in Capsida study of rare disease gene therapy | ||
| Do | FDA shares guidance to drugmakers developing non-opioid pain medicines | ||
| Mi | FDA clears J&J's drug-device combo for bladder cancer | ||
| Mi | Kriya, Odyssey secure 'megarounds'; Amgen boosts R&D leadership | ||
| Mi | Novo Nordisk to lay off 9,000 workers in major restructuring | ||
| Mi | [Podcast] The Progress Profile: Alzheimer's Research in Focus | ||
| 09.09. | Lilly to give biotech startups access to AI tools | ||
| 09.09. | Novartis to gain heart drug in $1.4B deal for Tourmaline Bio | ||
| 09.09. | BioNTech says dual-acting lung cancer drug helped shrink tumors | ||
| 08.09. | A new class of sleep drugs draws Wall Street's attention | ||
| 08.09. | Pfizer, BioNTech showcase new data supporting COVID booster | ||
| 08.09. | New Summit data clouds approval pathway in lung cancer | ||
| 08.09. | Rapport shares double on better-than-expected seizure drug data | ||
| 08.09. | A UK biotech takes aim at Parkinson's, ALS by drugging mitochondria | ||
| 08.09. | Driving precision oncology development: Integrated biomarker testing solutions that deliver impact | ||
| 08.09. | How sponsors are staying ahead in the obesity trial landscape |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .